Loading company…
Vigil Neuroscience develops microglia-based therapies for neurodegenerative diseases.
Founded in 2020 and based in Massachusetts, Vigil Neuroscience develops therapies for neurodegenerative diseases, including the VGL101 monoclonal antibody and small molecule TREM2 agonists. In August 2021, it raised USD 90 million in Series B funding led by Vida Ventures, with participation from Cormorant Asset Management, LLC, Deep Track Capital, Invus, Lightstone Ventures, Logos Capital Partners, OrbiMed Advisors, Pivotal bioVenture Partners, Rock Springs Capital, Surveyor Capital, Atlas Venture, Hatteras Venture Partners, and Northpond Ventures. As of November 2021, it had raised USD 120 million, and Dr. Ivana Magovcevic-Liebisch was President and CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in